Targeting p53 by small molecules in hematological malignancies

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Saha, Manujendra N ^a,b   Qiu, Lugui ^c   Chang, Hong ^a,b,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Apoptosis; Hematological malignancies; Leukemia; Lymphoma; MIRA 1; Myeloma; Nutlin; p53; PRIMA 1; RITA

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CHEMICALS AND DRUGS; GEMCITABINE; NUTLIN; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS; PROTEIN MDM2; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; RO 5045337; SELUMETINIB; SERDEMETAN; SORAFENIB; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE ARREST; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; SMALL MOLECULE LIBRARIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875359668     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-23     Document Type: Review

References (107)

1. Awakening guardian angels: drugging the p53 pathway. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP, Nat Rev Cancer 2009 9 862 873 10.1038/nrc2763 19935675
2. p53: a guide to apoptosis. Meulmeester E, Jochemsen AG, Curr Cancer Drug Targets 2008 8 87 97 10.2174/156800908783769337 18336191
3. The p53 knowledgebase: an integrated information resource for p53 research. Lim YP, Lim TT, Chan YL, Song AC, Yeo BH, Vojtesek B, Coomber D, Rajagopal G, Lane D, Oncogene 2007 26 1517 1521 10.1038/sj.onc.1209952 16953220
4. p53: twenty five years understanding the mechanism of genome protection. Gomez-Lazaro M, Fernandez-Gomez FJ, Jordán J, J Physiol Biochem 2004 60 287 307 10.1007/BF03167075 15957248
5. Characterization of the human p53 gene. Lamb P, Crawford L, Mol Cell Biol 1986 6 1379 1385 2946935
6. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Soussi T, Dehouche K, Beroud C, Hum Mutat 2000 2 105 213
7. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples. Pekova S, Mazal O, Cmejla R, Hardekopf DW, Plachy R, Zejskova L, Haugvicova R, Jancuskova T, Karas M, Koza V, Leuk Res 2011 35 889 898 10.1016/j.leukres.2010.12.016 21232794
8. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Nahi H, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C, Br J Haematol 2008 141 445 453 10.1111/j.1365-2141.2008.07046.x 18341636
9. TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Agirre X, Novo FJ, Calasanz MJ, Larráyoz MJ, Lahortiga I, Valgañón M, García-Delgado M, Vizmanos JL, Mol Carcinog 2003 38 201 208 10.1002/mc.10159 14639659
10. p53 deletion is not a frequent event in multiple myeloma. Avet-Loiseau H, Li JY, Godon C, Morineau N, Daviet A, Harousseau JL, Facon T, Bataille R, Br J Haematol 1999 106 717 719 10.1046/j.1365-2141.1999.01615.x 10468863
11. Clinical significance of TP53 mutation in myeloma. Chng WJ, Price-Troska T, Gonzalea-Paz N, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Leukemia 2007 21 582 584 10.1038/sj.leu.2404524 17215851
12. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Chang H, Qi C, Yi Q, Reece D, Stewart AK, Blood 2005 105 358 360 10.1182/blood-2004-04-1363 15339849
13. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, Mansoor A, Chen C, Masih-Khan E, Trieu Y, Blood 2009 114 522 525 10.1182/blood-2008-12- 193458 19332768
14. Surfing the p53 network. Vogelstein B, Lane D, Levine AJ, Nature 2000 408 307 310 10.1038/35042675 11099028
15. Mechanisms of p53-mediated apoptosis. Bates S, Vousden KH, Cell Mol Life Sci 1999 55 28 37 10.1007/s000180050267 10065149
16. Regulation and function of the p53 tumor suppressor protein. Ryan KM, Ernst MK, Rice NR, Vousden KH, Curr Opin Cell Biol 2001 13 332 337 10.1016/S0955-0674(00)00216-7 11343904
17. Targeting the p53 signaling pathway in cancer therapy-the promises, challenges and perils. Stegh AH, Expert Opin Ther Targets 2012 16 67 83 10.1517/14728222.2011.643299 22239435
18. Translational approaches targeting the p53 pathway for anti-cancer therapy. Essmann F, Schulze-Osthoff K, Br J Pharmacol 2012 165 328 344 10.1111/j.1476-5381.2011.01570.x 21718309
19. The tumor suppressor p53: from structures to drug discovery. Joerger AC, Fersht AR, Cold Spring Harb Perspect Biol 2010 2 000919 10.1101/cshperspect. a000919 20516128
20. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Shangary S, Wang S, Annu Rev Pharmacol Toxicol 2009 49 223 241 10.1146/annurev.pharmtox.48. 113006.094723 18834305
21. Therapeutic targeting of p53 by small molecules. Selivanova G, Semin Cancer Biol 2010 20 46 56 10.1016/j.semcancer.2010.02.006 20206268
22. New insights into p53 based therapy. Lane DP, Brown CJ, Verma C, Cheok CF, Discov Med 2011 12 107 117 21878188
23. Restoration of p53 to limit tumor growth. Wang W, El-Deiry WS, Curr Opin Oncol 2008 20 90 96 10.1097/CCO.0b013e3282f31d6f 18043262
24. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Science 2004 303 844 848 10.1126/science.1092472 14704432
25. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G, Nat Med 2004 10 1321 1328 10.1038/nm1146 15558054
26. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G, Nat Med 2002 8 282 288 10.1038/nm0302-282 11875500
27. Pharmacological reactivation of mutant p53: from protein structure to cancer patient. Wiman KG, Oncogene 2010 29 4245 4252 10.1038/onc.2010.188 20498645
28. Pharmacological rescue of mutant p53 conformation and function. Foster BA, Coffey HA, Morin MJ, Rastinejad F, Science 1999 286 2507 2510 10.1126/science.286.5449.2507 10617466
29. The tumor suppressor gene TP53: implications for cancer management and therapy. Seemann S, Maurici D, Olivier M, Caron de Fromentel C, Hainaut P, Crit Rev Clin Lab Sci 2004 41 551 583 10.1080/10408360490504952 15603511
30. Pharmacological activation of the p53 pathway in haematological malignancies. Saha MN, Micallef J, Qiu L, Chang H, J Clin Pathol 2010 63 204 209 10.1136/jcp.2009.070961 19955555
31. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Proc Natl Acad Sci USA 2006 103 1888 1893 10.1073/pnas.0507493103 16443686
32. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Gu L, Zhu N, Findley HW, Zhou M, Leukemia 2008 22 730 739 10.1038/leu.2008.11 18273046
33. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Zhu N, Gu L, Li F, Zhou M, Mol Cancer Ther 2008 7 1101 1109 10.1158/1535-7163.MCT-08-0179 18483299
34. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. Vilas-Zornoza A, Agirre X, Martín- Palanco V, Martín-Subero JI, San José-Eneriz E, Garate L, Álvarez S, Miranda E, Rodríguez-Otero P, Rifón J, PLoS One 2011 6 17012 10.1371/journal.pone.0017012 21386967
35. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Blood 2005 106 3150 3159 10.1182/blood-2005-02-0553 16014563
36. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M, Cell Cycle 2006 5 2778 2786 10.4161/cc.5.23.3520 17172851
37. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M, Cancer Res 2007 67 3210 3219 10.1158/0008-5472.CAN-06-2712 17409429
38. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Zhang W, Konopleva M, Burks JK, Dywer KC, Schober WD, Yang JY, McQueen TJ, Hung MC, Andreeff M, Cancer Res 2010 70 2424 2434 10.1158/0008-5472.CAN-09-0878 20215498
39. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G, Curr Drug Metab 2007 8 395 403 10.2174/138920007780655432 17504227
40. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M, Blood 2008 111 3742 3750 10.1182/blood-2007-05-091504 18187663
41. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H, Leukemia 2010 24 33 43 10.1038/leu.2009.212 19946262
42. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Thompson T, Andreeff M, Studzinski GP, Vassilev LT, Mol Cancer Ther 2010 9 1158 1168 10.1158/1535-7163.MCT-09-1036 20406950
43. Synergistic induction of p53 mediated apoptosis by valporic acid and nutlin-3 in acute myeloid leukemia. McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, Leukemia 2012 26 910 917 10.1038/leu.2011.315 22064349
44. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H, Leukemia 2008 22 1728 1736 10.1038/leu.2008.158 18548093
45. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P, Haematologica 2012 97 1722 1730 10.3324/haematol.2012.062083 22689683
46. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Secchiero P, Zerbinati C, Melloni E, Milani D, Campioni D, Fadda R, Tiribelli M, Zauli G, Neoplasia 2007 9 853 861 10.1593/neo.07523 17971905
47. NPMc(+) AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds. Lew QJ, Tan CH, Gurumurthy M, Chu KL, Cheong N, Lane DP, Chao SH, Cell Cycle 2011 10 1978 1987 10.4161/cc.10.12.15859 21558800
48. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H, Wang S, Malek SN, Blood 2010 116 71 80 10.1182/blood-2010-01-261628 20404136
49. Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity. Voltan R, Celeghini C, Melloni E, Secchiero P, Zauli G, Br J Haematol 2010 148 957 961 10.1111/j.1365-2141.2009.08018.x 19958355
50. Therapeutic advancement of chronic lymphocytic leukemia. Lu K, Wang X, J Hematol Oncol 2012 5 55 10.1186/1756-8722-5-55 22980425
51. Update in the management of chronic lymphocytic leukemia. Maddocks KJ, Lin TS, J Hematol Oncol 2009 2 29 10.1186/1756-8722-2-29 19619273
52. The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. Secchiero P, di Iasio MG, Melloni E, Voltan R, Celeghini C, Tiribelli M, Dal Bo M, Gattei V, Zauli G, Leukemia 2010 24 480 483 10.1038/leu.2009.215 19847196
53. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. Secchiero P, Melloni E, Tiribelli M, Gonelli A, Zauli G, J Leukoc Biol 2008 83 434 437 17998303
54. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Lasio MG, Gonelli A, Cavazzini F, Campioni D, Fanin R, Cuneo A, Blood 2006 107 4122 4129 10.1182/blood-2005-11-4465 16439677
55. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E, Campàs C, Barragán M, de Sevilla AF, Domingo A, Blood 2006 107 4109 4114 10.1182/blood-2005-08-3273 16439685
56. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity. Zauli G, di Iasio MG, Secchiero P, Dal Bo M, Marconi D, Bomben R, Del Poeta G, Gattei V, Curr Cancer Drug Targets 2009 9 510 518 10.2174/156800909788486777 19519319
57. MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3. Bo MD, Secchiero P, Degan M, Marconi D, Bomben R, Pozzato G, Gaidano G, Del Poeta G, Forconi F, Zauli G, Gattei V, Br J Haematol 2010 150 237 239 20507307
58. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M, Blood 2006 108 993 1000 10.1182/blood-2005-12-5148 16543464
59. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM, Cuneo A, Secchiero P, Clin Cancer Res 2011 17 762 770 10.1158/1078-0432.CCR-10- 2572 21106726
60. p53-mediated apoptosis of CLL cells: evidence for a transcription- independent mechanism. Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Nacheva EP, Howard-Reeves JD, Duke VM, Kottaridis PD, Cwynarski K, Blood 2008 112 3827 3834 10.1182/blood-2008-05-156380 18682598
61. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, Malek SN, Donato NJ, Wang S, Talpaz M, Leukemia 2011 25 761 769 10.1038/leu.2011.7 21350558
62. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Kurosu T, Wu N, Oshikawa G, Kagechika H, Miura O, Apoptosis 2010 15 608 620 10.1007/s10495-010-0457-0 20094798
63. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, Theurich S, Cigliano L, Manz RA, Daniel PT, Blood 2005 106 3609 3617 10.1182/blood-2005-04-1489 16081689
64. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Clin Cancer Res 2009 15 7153 7160 10.1158/1078-0432.CCR-09-1071 19934289
65. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways. Saha MN, Jiang H, Chang H, Cancer Biol Ther 2010 10 567 578 10.4161/cbt.10.6.12535 20595817
66. Nutlin's two roads toward apoptosis. Zhang Q, Lu H, Cancer Biol Ther 2010 10 579 581 10.4161/cbt.10.6.13127 20716967
67. Inhibition of p53-murine double minute 2 interaction by nutlin stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ, Clin Cancer Res 2007 13 3380 3387 10.1158/1078-0432.CCR-06-2581 17545546
68. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Janz M, Stühmer T, Vassilev LT, Bargou RC, Leukemia 2007 21 772 779 17268519
69. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ, Blood 2011 118 4140 4149 10.1182/blood-2011-03-340323 21844567
70. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ, Leukemia 2009 23 784 790 10.1038/leu.2008.348 19225536
71. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M, Cancer Lett 2010 299 161 170 10.1016/j.canlet.2010.08.015 20850924
72. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K, Miida T, Pittaluga S, Raffeld M, Clin Cancer Res 2009 15 933 942 10.1158/1078-0432.CCR-08-0399 19188164
73. The therapeutic potential of p53 reactivation by nutlin-3a in ALK + anaplastic large cell lymphoma with wild-type or mutated p53. Drakos E, Atsaves V, Schlette E, Li J, Papanastasi I, Rassidakis GZ, Medeiros LJ, Leukemia 2009 23 2290 2299 10.1038/leu.2009.180 19741726
74. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM, J Hematol Oncol 2012 5 57 10.1186/1756-8722-5-57 22989009
75. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F, Medeiros LJ, Leukemia 2011 25 856 867 10.1038/leu.2011.28 21394100
76. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. Renouf B, Hollville E, Pujals A, Tétaud C, Garibal J, Wiels J, Leukemia 2009 23 1557 1563 10.1038/leu.2009.92 19421231
77. New targets for the treatment of follicular lymphoma. Tageja N, Padheye S, Dandawate P, Al-Katib A, Mohammad RM, J Hematol Oncol 2009 2 50 10.1186/1756-8722-2-50 20030851
78. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM, Mol Cancer 2009 8 115 10.1186/1476-4598-8-115 19958544
79. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S, Leukemia 2009 23 2090 2101 10.1038/leu.2009.171 19710698
80. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G, Cancer Cell 2009 15 171 183 10.1016/j.ccr.2009.01.019 19249676
81. Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA. Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ, Mol Cancer Ther 2012 11 2243 2253 10.1158/1535-7163.MCT-12-0135 22933706
82. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis. Kazemi A, Safa M, Shahbazi A, Hematology 2011 16 225 231 10.1179/102453311X12953015767536 21756539
83. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Saha MN, Jiang H, Muaki A, Chang H, Mol Cancer Ther 2010 9 3041 3051 10.1158/1535-7163.MCT-10-0471 21062913
84. RITA-induced apoptosis of multiple myeloma cells is mediated by activation of JNK signaling. Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Chang H, Blood (ASH Annual Meeting Abstracts) 2011 118 1836
85. Targeting p53 by small molecule p53 activators in multiple myeloma [abstract]. Saha MN, Yang Y, Chang H, J Hematol Oncol 2012 5 Suppl 1 7
86. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Krajewski M, Ozdowy P, D'Silva L, Rothweiler U, Holak TA, Nat Med 2005 11 1135 1136 10.1038/nm1105-1135 16270059
87. Targeting p53 via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma. Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Qiu L, Chang H, PLoS One 2012 7 30215 10.1371/journal.pone.0030215 22276160
88. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman KG, Paul C, Br J Haematol 2006 132 230 236 10.1111/j.1365-2141.2005.05851.x 16398657
89. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ, Cancer Cell 2009 15 376 388 10.1016/j.ccr.2009.03.003 19411067
90. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Bykov VJ, Issaeva N, Selivanova G, Wiman KG, Carcinogenesis 2002 23 2011 2018 10.1093/carcin/23.12.2011 12507923
91. Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, J Clin Oncol 2012 30 3633 3639 10.1200/JCO.2011.40.7783 22965953
92. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C, Merup M, Br J Haematol 2004 127 285 291 10.1111/j.1365-2141.2004.05210.x 15491287
93. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Ali D, Jönsson-Videsäter K, Deneberg S, Bengtzén S, Nahi H, Paul C, Lehmann S, Eur J Haematol 2011 86 206 215 10.1111/j.1600-0609.2010.01557.x 21114538
94. p53-independent anti-myeloma activity of Prima- 1§ssup§met§esup§ Saha MN, Jiang H, Mei-His C, Chang H, Blood (ASH Annual Meeting Abstracts) 2011 118 1826
95. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG, J Biol Chem 2005 280 30384 30391 10.1074/jbc.M501664200 15998635
96. A novel small molecule MIRA-1 induces cytotoxicity in multiple myeloma cells harbouring wild type or mutant p53. Saha MN, Jiang H, Chang H, Modern Pathology 2012 25 (Suppl 2) 1534 22766788
97. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T, Tai YT, Leiba A, Pines M, Richardson PG, Nagler A, Anderson KC, Br J Haematol 2012 157 718 731 10.1111/j.1365-2141.2012. 09120.x 22533681
98. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M, Cancer 2012 118 1023 1031 10.1002/cncr.26360 21761401
99. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Kojima K, Burks JK, Arts J, Andreeff M, Mol Cancer Ther 2010 9 2545 2557 10.1158/1535-7163.MCT- 10-0337 20736344
100. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Blood 2010 115 5202 5213 10.1182/blood-2009-12-259523 20382844
101. Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics. Wang S, Zhao Y, Bernard D, Aguilar A, Kumar S, Top Med Chem 2012 8 57 80 10.1007/978-3-642-28965-1-2
102. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H, Cancer Biol Ther 2010 9 936 944 10.4161/cbt.9.11.11882 20418664
103. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Surget S, Chiron D, Gomez-Bougie P, Descamps G, Ménoret E, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C, Cancer Res 2012 72 4562 4573 10.1158/0008-5472.CAN-12-0487 22738917
104. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK, Oncogene 2007 26 3473 3481 10.1038/sj.onc.1210136 17146434
105. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Lau LM, Nugent JK, Zhao X, Irwin MS, Oncogene 2008 27 997 1003 10.1038/sj.onc.1210707 17700533
106. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E, Frolova EI, Kovriga I, Gudkov AV, Feinstein E, Proc Natl Acad Sci USA 2008 105 6302 6307 10.1073/pnas.0802091105 18424558
107. p53 family: at the crossroads in cancer therapy. Alsafadi S, Tourpin S, André F, Vassal G, Ahomadegbe JC, Curr Med Chem 2009 16 4328 4344 10.2174/092986709789578196 19754415